Subject(s)
Humans , Male , Young Adult , Follicular Cyst/diagnosis , Skin Neoplasms/diagnosis , Neoplasms, Basal Cell/diagnosisSubject(s)
Humans , Male , Young Adult , Follicular Cyst/diagnosis , Skin Neoplasms/diagnosis , Neoplasms, Basal Cell/diagnosis , BiopsyABSTRACT
BACKGROUND AND OBJECTIVE: Frontal fibrosing alopecia is an increasingly common form of scarring alopecia. The aim of this study was to describe the demographic and clinical characteristics of patients with FFA seen at the trichology unit of a medium-sized regional hospital and to report on treatments used. MATERIAL AND METHOD: We reviewed the medical records of all patients with FFA seen at the trichology unit of Hospital Universitario Infanta Sofía in Madrid, Spain between May 2016 and May 2018. We analyzed associations between disease severity, clinical patterns, need for oral medications, and other characteristics. RESULTS: Seventy-five patients (73 women and 2 men) were studied. Diagnosis was clinical in most cases and 13 cases (17.3%) were confirmed histologically. Median (interquartile range) age at reported onset of symptoms was 61 (12) years. Involvement of the eyebrows was recorded in 70 patients (93.3%) and signs of oral and genital lichen planus in 7 (9.6%). Eleven patients (14.7%) had hypothyroidism and 15 (20.0%) had signs of rosacea. Only 5 of the patients who presented a linear pattern (21.7%) had severe hairline recession. Patients with unstable and/or symptomatic disease (n=24) were treated with oral medications (5-alpha reductase inhibitors, hydroxychloroquine, corticosteroids, and isotretinoin) or intralesional corticosteroids. Eighteen patients (75.0%) achieved disease stability. Ten of the 15 patients with signs of rosacea and 10 of those with facial papules required systemic treatment. CONCLUSION: Most of the patients in this series of FFA were postmenopausal women. The prevalence of oral and genital lichen planus was higher than that observed in the general population. Patients with a linear pattern had less severe disease. Facial papules were more common in younger patients and both facial papules and rosacea were associated with a greater need for oral treatment.
Subject(s)
Forehead , Lichen Planus , Alopecia/drug therapy , Female , Humans , Lichen Planus/drug therapy , Male , Retrospective Studies , SpainSubject(s)
COVID-19/complications , Eosinophilia/etiology , Panniculitis/etiology , SARS-CoV-2 , Adult , Biopsy , Eosinophilia/pathology , Female , Humans , Panniculitis/pathology , Skin/pathologyABSTRACT
No disponible
Subject(s)
Humans , Female , Child , Dermatitis, Allergic Contact/diagnosis , Skin Tests/methods , Ointments/adverse effects , Oleic Acids/adverse effects , Skin Irritancy Tests/methods , Dermatitis, Allergic Contact/drug therapy , Ointments/administration & dosage , Axilla/injuriesSubject(s)
Dermatitis, Allergic Contact/etiology , Oleic Acids/adverse effects , Child , Female , Humans , OintmentsABSTRACT
The treatment of inflammatory and autoimmune diseases is challenging because of their frequency and complexity. Treatment of these diseases is based on the suppression of the patient's immune system using corticosteroids, corticosteroid-sparing immunosuppressive agents, and biologic drugs, making an understanding of the management of immunosuppressive therapy essential. Before an immunosuppressive agent is prescribed, a study must be carried out to identify contraindications, detect latent infections, and determine the most appropriate dose. During treatment, regular monitoring is required to detect adverse effects. The clinician must be familiar with the time lag between start of treatment and onset of the immunosuppressive effect as well as the maximum recommended duration of treatment and cumulative dose for each drug. As dermatologists we are accustomed to using these immunosuppressive agents, but we should have a good knowledge of the guidelines for their use and the monitoring required in each case if we are to reduce variability and avoid potentially serious adverse effects.
Subject(s)
Dermatology/methods , Immunosuppressive Agents/therapeutic use , Skin Diseases/drug therapy , Adrenal Cortex Hormones/therapeutic use , Antirheumatic Agents/therapeutic use , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Contraindications, Drug , Dermatitis/drug therapy , Dermatitis/immunology , Drug Monitoring , Humans , Immunosuppressive Agents/adverse effects , Skin Diseases/immunology , VaccinationABSTRACT
Gouty panniculitis is caused by the deposition of urate crystals in the subcutaneous tissue, accompanied by a lobular panniculitis. It presents as subcutaneous nodules, most commonly located on the lower extremities. Being an unusual clinical presentation of gout, the sonographic findings of gouty panniculitis have been scarcely described in the literature. Our report describes the ultrasound features we found in a case of gouty panniculitis and the usefulness of this technique for diagnosis and monitoring of this disease.
Subject(s)
Gout/complications , Panniculitis/diagnostic imaging , Ultrasonography , Adult , Humans , Male , Panniculitis/etiology , Panniculitis/pathologyABSTRACT
In 1936, Covisa and Bejarano published a treatise entitled Elementos de Dermatología (The Elements of Dermatology). In this surprisingly modern book they abandoned the nosological debates characteristic of the 19th century and instead classified diseases according to their etiology and pathogenesis based on the scientific and technical advances of the time. Moreover, unlike other books available at the time, which were essentially adaptations of foreign texts, this was the first medical work to reflect the reality of Spanish medicine. However, the future of both the book and its authors was to be determined by the start of the Spanish Civil War in the same year. Covisa and Bejarano, who were both extremely active in the public health system and medical education during the Second Republic, were obliged to seek exile in America. Due to the difficulties of the time, very few copies of the book reached the public and no new editions were ever printed. We will never know what would have happened if the war had not started, but we believe that this important work should be remembered.
Subject(s)
Dermatology/history , Publishing/history , History, 20th Century , Skin Diseases/history , SpainABSTRACT
Animal-type melanoma is a rare variant of malignant melanoma in humans. Although many patients develop locoregional and distant metastases, mortality is lower than in other types of melanoma. We present 3 cases of animal-type melanoma in elderly men and include a description of common clinical and dermoscopic features (homogeneous blue pattern, irregular whitish structures, and irregular large vessels).
Subject(s)
Dermoscopy , Melanoma/pathology , Skin Neoplasms/pathology , Aged , Aged, 80 and over , Humans , Male , Melanoma/classification , Skin Neoplasms/classificationABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Vascular Calcification/chemically induced , Teriparatide/adverse effects , Calciphylaxis/diagnosis , Calcinosis/chemically inducedABSTRACT
La atopia se acompaña de forma casi constante de una producción elevada de inmunoglobulina E (IgE). Omalizumab es un anticuerpo monoclonal anti-IgE, que actualmente está indicado en pacientes con asma que cumplen determinados criterios. Se han publicado algunos estudios sobre la utilidad del omalizumab en el tratamiento de la dermatitis atópica (DA), con resultados variables. Presentamos nuestra experiencia en 9 pacientes con dermatitis atópica grave, refractaria al menos a dos fármacos sistémicos. Todos los pacientes tratados referían una disminución del prurito y una mejoría en su calidad de vida. Los que presentaban asma consiguieron un buen control desde el punto de vista respiratorio, sin precisar otros tratamientos adicionales. En dos casos se consiguió un buen control en monoterapia, apreciándose una discreta mejoría de las lesiones de eccema en 4 de ellos. El omalizumab es un fármaco bien tolerado y seguro. Puede ser útil en el tratamiento de pacientes con DA grave, refractaria a otros tratamientos sistémicos. Este anticuerpo monoclonal anti-IgE abre la puerta a los tratamientos inmunomoduladores sistémicos para el manejo de la DA, lo que supone un gran avance terapéutico (AU)
Atopy is almost always associated with an elevated immunoglobulin (Ig) E production. Omalizumab is a monoclonal anti-IgE antibody that is currently indicated for the treatment of cases of asthma that satisfy certain criteria. A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. We present our experience in the treatment of 9 patients with severe atopic dermatitis refractory to at least 2 systemic drugs. All patients reported a decrease in pruritus and an improvement in quality of life. Good control of the skin disease was achieved with omalizumab in monotherapy in 2 patients, and there was a slight improvement in the eczematous lesions in 4 patients. Those patients who also had asthma achieved good control of their respiratory symptoms and did not require additional therapy. Omalizumab is a well-tolerated and safe drug that can be useful for the treatment of severe atopic dermatitis refractory to other systemic therapies. This monoclonal anti-IgE antibody is a major therapeutic advance as it opens the door to the management of atopic dermatitis using systemic immunomodulating therapies (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Immunoglobulins , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/prevention & control , Dermatitis, Atopic/therapy , Eczema , Asthma/complications , Pruritus , Quality of Life , Case ReportsABSTRACT
Atopy is almost always associated with an elevated immunoglobulin (Ig) E production. Omalizumab is a monoclonal anti-IgE antibody that is currently indicated for the treatment of cases of asthma that satisfy certain criteria. A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. We present our experience in the treatment of 9 patients with severe atopic dermatitis refractory to at least 2 systemic drugs. All patients reported a decrease in pruritus and an improvement in quality of life. Good control of the skin disease was achieved with omalizumab in monotherapy in 2 patients, and there was a slight improvement in the eczematous lesions in 4 patients. Those patients who also had asthma achieved good control of their respiratory symptoms and did not require additional therapy. Omalizumab is a well-tolerated and safe drug that can be useful for the treatment of severe atopic dermatitis refractory to other systemic therapies. This monoclonal anti-IgE antibody is a major therapeutic advance as it opens the door to the management of atopic dermatitis using systemic immunomodulating therapies.
Subject(s)
Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatologic Agents/therapeutic use , Adult , Combined Modality Therapy , Dermatitis, Atopic/immunology , Dermatitis, Atopic/radiotherapy , Drug Evaluation , Female , Humans , Immunoglobulin E/immunology , Immunosuppressive Agents/therapeutic use , Male , Omalizumab , PUVA Therapy , Pruritus/drug therapy , Pruritus/etiology , Quality of Life , Retrospective Studies , Treatment Outcome , Ultraviolet TherapyABSTRACT
Presentamos una mujer con telangiectasias puntiformes asintomáticas en miembros superiores de varios años de evolución. Tras descartar un proceso sistémicosubyacente fue diagnosticada de telangiectasia esencial generalizada. Solo destacó la presencia de niveles elevados de anticuerpos antitiroideos.La telangiectasia esencial generalizada es una enfermedad benigna, lentamente progresiva que suele aparecer en mujeres adultas y que se caracterizapor el desarrollo de numerosas telangiectasias cutáneas. Para su diagnóstico es necesario excluir otras causas de telangiectasias como sífilis o enfermedadesautoinmunes del tejido conjuntivo. Los nuevos láser se están mostrando como una alternativa segura y eficaz de tratamiento (AU)
A 54-year-old woman with a several years history of asyntomatic punctate telangiectases on her upper limbs is presented. A systemic disease was ruledout, and she was diagnosed as generalized essential telangiectasia. Only the presence of increased levels of anthyroid antibodies were emphasized.Generalized essential telangiectasia is a benign, slowly progressive condition that usually appears in adult women and is characterized by the developmentof numerous cutaneous telangiectases. Exclusion of other causes of telangiectases, like syphilis and autoimmune connective tissue diseases, isnecessary to achieve the diagnosis of generalized essential telangiectasia. Laser therapy is becoming as a save and effective treatment (AU)
Subject(s)
Humans , Female , Middle Aged , Telangiectasis/diagnosis , Diagnosis, DifferentialABSTRACT
INTRODUCTION: Turpentine is an oleoresin obtained from various species of pine. It contains a volatile oil (oil of turpentine) which is responsible for its properties and this is the form generally used. Opportunity for contact with turpentine is widespread. It is universally used as a solvent to dissolve and thin lacquers, varnishes and paints. It is also an ingredient in many liniments and cold remedies. Turpentine is regarded as both a local irritant and a sensitizer. Cases of allergic contact dermatitis in painters, mechanics, shoe repairers and home decorators have been reported. CASE REPORT: We report a case of a non-professional painter who developed a contact allergic dermatitis due to his exposure to turpentine while doing oil-painting as a hobby. DISCUSSION: Dermatitis is one of the biggest dangers of working with art materials and occupational contact dermatitis is often detected on the hands of the painters. Solvents are indispensable and turpentine is the most important and the traditional one used in oil-painting. Contact allergy to oil of turpentine was reported to have become rare in Europe but over the last few years, increased rates of turpentine sensitization have been reported.
Subject(s)
Dermatitis, Allergic Contact/etiology , Occupational Exposure/adverse effects , Turpentine/adverse effects , Aged , Hobbies , Humans , Immunization , Irritants/adverse effects , Male , Oils/adverse effects , Paintings , Solvents/adverse effectsABSTRACT
La protrusión perineal infantil es una entidad descrita recientemente, con una morfología de las lesiones, localización y prevalencia características, sobre todo en las niñas prepuberales. Presentamos un nuevo caso de esta infrecuente entidad
Infantile perineal pyramidal protrusion is a recently recognized condition characterized by the morphology and location of the lesions and its prevalence in prepubertal girls. We present a new case of this uncommon entity
